In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code:
Cambridge, MA, - - Biogen Inc. (Nasdaq: BIIB) announced today that Robin Kramer, Chief Financial Officer, and Adam Keeney, Head of Corporate Development, will participate in a fireside chat during the Wells Fargo 21st Annual Healthcare Conference. The webcast will be live on Wednesday, Sept 9,
SAN DIEGO --(BUSINESS WIRE)--Aug. 25, 2026-- Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that
Both doses of SPY072 demonstrated statistically significant benefits compared to placebo on one or more of the primary (change from baseline in DAS28-CRP), key secondary (ACR20), and exploratory endpoints (e.g., ACR50) SPY072 was well tolerated with rates of adverse events comparable to placebo
COPENHAGEN, Denmark, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its participation at ISDS 2026, the annual meeting of the International Skeletal Dysplasia Society being held in Toronto, Canada, from August 26-29, 2026, will include an oral presentation
Ziihera plus tislelizumab and chemotherapy approved for first-line treatment of all HER2+ GEA patients (IHC 3+ and IHC 2+/ISH+) regardless of PD-L1 status, providing a new treatment option in front-line GEA Second FDA approval for zanidatamab in less than two years further validates Zymeworks’
Ziihera plus tislelizumab and chemotherapy approved for first-line treatment of all HER2+ GEA patients (IHC 3+ and IHC 2+/ISH+) regardless of PD-L1 status, establishing a new standard of care in front-line GEA Company to host investor webcast on Aug. 25 at 4:30 p.m. ET For U.S.
Human studies show that the TGF-β trap and IL-15 fusion used alone promotes expansion of progenitor CD8 + T cells and NK cells Company has incorporated the TGF-β/IL-15 moiety into the constructs of its second-generation fusion immunotherapeutics constructed with novel TRBC drug development platform
Media Release COPENHAGEN, Denmark; August 25, 2026 Genmab A/S (Nasdaq: GMAB) announced today that members of its E xecutive Committee will participat e in fireside chats at the following investor conferences in September 2026: Wells Fargo 21st Annual Healthcare Conference in Boston on September
REZOLVE-AD study met all primary and key secondary endpoints, including EASI -75, EASI -90, Itch NRS, vIGA-AD and BSA, on rezpegaldesleukin 24 µg/kg q2w First large, placebo-controlled trial to support T-reg modulation as a clinical mechanism for immunoregulation of chronic inflammatory disease
EMERYVILLE, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Rajiv Patni, M.D., as Chief Medical Officer. Dr.
ROCKVILLE, Md., Aug. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026. With multiple upcoming catalysts across its late-stage pipeline of potential first-and best-in-class gene therapies, Mr.
RNS Number: 0041S PureTech Health PLC 25 August 2026 25 August 2026 PureTech Health plc PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress Presentations will highlight Celea's differentiated approach to
MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and
— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to
Houston, Texas and Tuebingen, Germany, August 25, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, announced today that it has agreed to sell 12,945,916
All clinical trial sites identified and CRO retained Patient screening expected to begin in October 2026, with first patient to be enrolled shortly after FOSTER CITY, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company
Management to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, Aug. 25, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its
25 August 2026 AstraZeneca prices €2.55 billion bond offering AstraZeneca PLC (the Company) announces that, on 24 August 2026, its wholly owned subsidiary AstraZeneca Finance LLC, successfully priced four tranches of Eurobonds totalling €2.55 billion (the Offering)....
DLL3-targeting Radio-DARPin MP0712 progressing in Phase 1/2a trial, now recruiting at dose level 2; initial data expected in 2026, efficacy data expected in 2027 CD70 selected as new radio target for the treatment of kidney cancer and other indications, with clinical program start anticipated in
Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open Topco common stock expected to commence trading on Nasdaq
– Alixorexton Demonstrated Statistically Significant and Clinically Meaningful Improvements in Wakefulness and Cataplexy – – At All Doses Tested, Alixorexton Demonstrated Clinically Meaningful Improvements in Patient-Reported Outcomes Related to Disease Severity, Fatigue, Cognition and
MENLO PARK, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis
SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it
Proprietary DehydraTECH 3.0 amycretin tablet formulation more than doubled absolute bioavailability compared to a leading industry study Proprietary DehydraTECH 3.0 retatrutide tablet formulation increased drug absorption by as much as an astonishing 4,552% compared to the DehydraTECH 2.0 retatrutide tablet evaluated Findings support Lexaria’s expanding...
Ionis partner GSK announces Hibsago (bepirovirsen) approved in Japan as first and only functional cure for chronic hepatitis B August 24, 2026 – Ionis partner GSK today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Hibsago (bepirovirsen) as a functional cure for
LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders Lexicon is eligible to receive up to $1 billion in total upfront and milestone payments from the collaboration, plus royalties on net sales THE
LEQEMBI IQLIK is the first-of-its-kind anti-amyloid treatment worldwide offering at-home dosing for initiation and maintenance (approved in the U.S.) TOKYO and CAMBRIDGE, Mass., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB), announced today that once weekly
- Former Deputy Director of the FDA’s Office of Neuroscience - Dr. Lee has previously advised AEON through Clintrex Research LLC (Clintrex), an affiliate of BlueRidge Life Sciences, on the regulatory strategy for ABP-450 ALISO VIEJO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc.
FDA Found Spruce's Chemistry, Manufacturing and Controls (CMC) Comparability Strategies Reasonable to Support the BLA Following Technology Transfer to Leading Global Biologics Manufacturer Spruce and FDA Aligned on the Overall Content and Format of the Planned BLA, Including Structure of the
– Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Administration (FDA) in November 2026 – – Supplemental BLA will be supported by results from three Phase 3 studies of ATEV, including results from V012 dialysis access study in women – – The V012 dialysis
Designation follows encouraging Phase 1 activity across multiple tumor types including 2L+ KRAS G12X pancreatic cancer Three potentially registration-enabling trials planned across pancreatic and lung cancers Additional Phase 1 monotherapy and combination data expected in H1 2027 SAN DIEGO, Aug.
- Detailed results from the Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia will be presented as a HOT LINE Late-Breaking Science Session on August 30, 2026 - - Arrowhead will host a webcast to review ESC data and Q&A on August 31, 2026 - PASADENA,
Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum Investor webinar scheduled for August 26, 2026 at 11:00 a.m. EDT JERUSALEM, August 24, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (Nasdaq:...
ROCKVILLE, Md., Aug. 24, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today provided an update on its investigational gene therapy, RGX-121 (clemidsogene lanparvovec), for the treatment of Mucopolysaccharidosis type II (MPS II), also known as Hunter Syndrome. The U.S.
Topline 26-week primary endpoint data from COVALENT-211 in insulin deficient type 2 diabetes (“T2D”) patients who are not achieving glycemic targets despite antihyperglycemic medications anticipated in the first quarter of 2027 COVALENT-212 Phase II enrollment T2D patients who are not achieving
BOSTON and SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric
Study will evaluate PSA and RECIST response, duration of response, radiographic progression-free survival (rPFS), and safety Updated data from the initial Phase 1/2 study of MRT-2359 plus enzalutamide in patients with advanced CRPC expected by end of year BOSTON, Aug.
BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today
Dr. Trenor brings more than two decades of clinical, translational and drug development leadership experience advancing innovative therapies across rare diseases, hematology and oncology MENLO PARK, Calif. --(BUSINESS WIRE)--Aug. 24, 2026-- AN2 Therapeutics, Inc.
-First patient dosed with PBGENE-DMD, the first clinical gene-editing program for DMD – -First patient dosed at Arkansas Children’s Hospital, a PPMD Certified Duchenne Care Center and designated MDA Care Center– DURHAM, N.C. --(BUSINESS WIRE)--Aug. 24, 2026-- Precision BioSciences, Inc.
The PIONEER program marks a key step toward potential first-in-class neuroprotection for optic neuritis and other neurological diseases, supported by positive Acuity Phase 2 data, FDA Breakthrough Therapy and EMA PRIME designations, and recent positive feedback from the FDA Neurology Division.
If approved, Jemperli could eliminate the need for chemotherapy, radiation, and surgery for some patients.